Medicament for liver regeneration and for treatment of liver failure
The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
1. A method of treating liver failure in a subject in need thereof, comprising administering to the subject an effective amount of a compound, wherein the compound is an inhibitor of the activity of MKK4, wherein MKK4 is encoded by mRNA with SEQ ID NO: 1204, and wherein the compound is selected from the group consisting of:
Compound
Structural formula
SYN22174524 5-[2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl]-7- oxo-N-phenyl- 1H-pyrazolo- [1,5-a]- pyrimidine-3- carboxamide
SYN22174787; 5-[2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl]-3-(4- fluorophenyl)- 1H-pyrazolo- [1,5-a]- pyrimidin- 7-one
SYN22175977; 5-[2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl]-3-(4- methylphenyl)- 1H-pyrazolo- [1,5-a]- pyrimidin- 7-one
SYN22176267; 3-(4-chloro- phenyl)-5- [2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl]-2- (methoxy- methyl)- 1H-pyrazolo- [1,5-a]- pyrimidin- 7-one
SYN22176367; 5-[2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl]-2- (methoxy- methyl)-3- (4-methyl- phenyl)-1H- pyrazolo- [1,5-a]- pyrimidin- 7-one
SYN22176842; 5-[2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl]-2- (3-methoxy- phenyl)-3- methyl- pyrazolo- [5,1-b]- pyrimidin-7-ol
SYN22136990; 5-[2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl]-2- (2-methoxy- phenyl)-3- methyl- pyrazolo- [5,1-b]- pyrimidin-7-ol
SYN22177890; 3-(4-chloro- phenyl)-5-[2- (3,5-dimethyl- 1H-pyrazol-4- yl)ethyl]-2- methyl-1H- pyrazolo- [1,5-a]- pyrimidin- 7-one
IUPAC Name; 5-[2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl)-7- oxo-N- phenyl-1H- pyrazolo- [1,5-a]- pyrimidin-3- carboxamide
IUPAC Name; 5-[2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl)-3- (4-methyl- phenyl)-1H- pyrazolo- [1,5-a]- pyrimidin- 7-one
IUPAC Name; 5-[2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl)-2- (methoxy- methyl)-3- phenyl-1H- pyrazolo- [1,5-a]- pyrimidin- 7-one
IUPAC Name; 3-(4-chloro- phenyl)-5- [2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl)-2- (methoxy- methyl)-1H- pyrazolo- [1,5-a]- pyrimidin- 7-one
IUPAC Name; 5-[2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl]-2- (methoxy- methyl)- 3-(4-methyl- phenyl)-1H- pyrazolo- [1,5-a]- pyrimidin- 7-one
2-(3,4- dimethoxy- phenyl)-5- [2-(3,5- dimethyl-1H- pyrazol-4- yl)ethyl]- pyrazolo- [5,1-b]- pyrimidin- 7-ol
5-[2-(3,5- dimethyl- 1H-pyrazol- 4-yl)ethyl]- 2-(3-methoxy- phenyl)-3- methyl- pyrazolo- [5,1-b]- pyrimidin- 7-ol
5-[2-(3,5- dimethyl- 1H-pyrazol- 4-yl)ethyl]- 2-(2-methoxy- phenyl)-3- methyl- pyrazolo- [5,1-b]- pyrimidin- 7-ol
5-[2-(3,5- dimethyl- 1H-pyrazol- 4-yl)ethyl]- 3-methyl- 2-(2-thionyl)- pyrazolo- [5,1-b]- pyrimidin- 7-ol
IUPAC Name; 5-[2-(3,5- dimethyl- 1H-pyrazol- 4-yl)ethyl]- 2-methyl- 3-phenyl- 1H-pyrazolo- [1,5-a]- pyrimidin- 7-one
5-[2-(3,5- dimethyl- 1H-pyrazol- 4-yl)ethyl]- 2-(4-fluoro- phenyl)- pyrazolo- [5,1-b]- pyrimidin- 7-one
and
IUPAC Name; 3-(4-chloro- phenyl)- 5-[2-(3,5- dimethyl- 1H-pyrazol- 4-yl)ethyl]- 1H-pyrazolo- [1,5-a]- pyrimidin- 7-one
2. A method according to claim 1 , wherein the compound comprises a liposome or lipid nanoparticle formulation.
3. A method according to claim 1 , wherein the compound is formulation as a composition comprising at least one pharmaceutically acceptable excipient.